India ¡ UTI ¡ Typhoid ¡ Respiratory ¡ GI Infection ¡ Gonorrhoea ¡ Cifran ¡ Ciplox ¡ Ciprobid ¡ Quintor ¡ Zoxan
â Children <18 yr (cartilage damage)
â Pregnancy & breastfeeding
â ī¸ Tendon rupture risk â stop if tendon pain (Achilles most common). Risk â with steroids, elderly, renal failure.
â ī¸ QT prolongation â avoid with other QT drugs
â ī¸ Avoid with antacids, calcium, iron, zinc â chelation reduces absorption. Separate by 2h.
â ī¸ High resistance in India â check C&S for UTI
Ciprofloxacin (Cifran, Ciplox, Ciprobid) is a second-generation fluoroquinolone with excellent Gram-negative coverage including Pseudomonas aeruginosa, Salmonella, E. coli, Klebsiella, Shigella, and Neisseria species. It has high oral bioavailability (~80%), making oral therapy equivalent to IV for most indications, and excellent tissue penetration including into the prostate, bone, and lung. It remains an important antibiotic in Indian clinical practice, but rising resistance â particularly in E. coli causing UTIs â has significantly reduced its empirical utility for many common indications in India.
Ciprofloxacin resistance in India is critically high. Studies from multiple Indian centres show E. coli resistance to ciprofloxacin of 50â80% in community UTI isolates, and even higher in hospital-acquired infections. Salmonella Typhi (typhoid) increasingly shows reduced susceptibility to fluoroquinolones in India â the NVBDCP now recommends azithromycin as first-line for uncomplicated typhoid because of this resistance pattern. Ciprofloxacin should ideally be used only when culture and sensitivity confirms susceptibility â empirical use for UTI without culture is associated with frequent treatment failures in India.
All fluoroquinolones including ciprofloxacin carry a risk of tendinopathy and tendon rupture, most commonly affecting the Achilles tendon but also the rotator cuff, quadriceps, and hand. The FDA and MHRA have issued black box warnings. Risk factors in India: concurrent corticosteroid use, age over 60, renal failure (drug accumulation), and participation in sports. Patients should be counselled to stop ciprofloxacin immediately and seek review if they develop tendon pain, swelling, or difficulty walking. This is an underrecognised adverse effect in Indian primary care.
Ciprofloxacin undergoes chelation with divalent cations (calcium, magnesium, aluminium, iron, zinc) â forming poorly absorbed complexes. In India, where patients commonly take antacids (Gelusil, Digene), calcium supplements, iron tablets, or antacid-containing medications alongside antibiotics, this interaction significantly reduces ciprofloxacin absorption and treatment efficacy. Separate ciprofloxacin from any calcium, antacid, iron, or zinc product by at least 2 hours before or 6 hours after. Milk, curd, and paneer (dairy) also reduce absorption â take ciprofloxacin with plain water on an empty stomach.